Aussagekraft der Tumormarker CA 125, CA 19-9, CA 15-3 und CEA bei Endometriose

The study measured serum tumor markers CA 125, CA 19-9, CA 15-3, and CEA in 42 women with histologically verified genital external endometriosis who received a 6-month course of the LHRH analogue buserelin. Pre-treatment sensitivity for detecting endometriosis was highest for CA 125 (49%) and low for CA 19-9 and CA 15-3 (both 19%), with CEA showing 0% sensitivity, and CA 125 had only a weak, nonconvincing correlation with AFS stage (r = 0.40); after treatment, marker–stage correlations were even less clear. Only CA 125 significantly decreased during therapy (p < 0.05), closely paralleling therapy-induced hypoestrogenism, and the authors conclude that measuring these markers cannot replace surgical/histologic diagnostic procedures. This paper is centrally about endometriosis—specifically evaluating the diagnostic and treatment-monitoring value of tumor markers (CA 125, CA 19-9, CA 15-3, CEA) in endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works